drugset / Trial / NCT00192504
Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety of motavizumab (MEDI-524) following a single intravenous dose in children hospitalized with respiratory syncytial virus (RSV).
Timeline
- Start
- 2004-03
- Primary completion
- 2005-01
- Completion
- 2005-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Motavizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Motavizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Motavizumab | Monoclonal antibody | 30 mg/kg | Intravenous |